

Antineoplastics and Adjunctive Therapies - Imidazotetrazines – Oral

Medical policy no. 21.10.40

Effective Date: October 1st, 2021

Note: New-to-market drugs included in this class based on the Apple Health Preferred Drug List are non-preferred and subject to this prior authorization (PA) criteria. Non-preferred agents in this class require an inadequate response or documented intolerance due to severe adverse reaction or contraindication to at least TWO preferred agents. If there is only one preferred agent in the class documentation of inadequate response to ONE preferred agent is needed. If a drug within this policy receives a new indication approved by the Food and Drug Administration (FDA), medical necessity for the new indication will be determined on a case-by-case basis following FDA labeling.

To see the list of the current Apple Health Preferred Drug List (AHPDL), please visit: <https://www.hca.wa.gov/assets/billers-and-providers/apple-health-preferred-drug-list.xlsx>

Background:

The antineoplastics and adjunctive therapies are classes of medications used for the treatment of cancer and cancer-related conditions.

Medical necessity:

Drug	Medical Necessity
Temozolomide (TEMODAR)	<p>Temozolomide may be considered medically necessary when used for:</p> <ol style="list-style-type: none"> conditions listed under Indications and Usage in approved drug labeling (prescribing information) from the Food and Drug Administration (FDA); OR conditions listed as medically-accepted indications in any of the compendia of drug information recognized by Medicaid

Clinical policy:

Drug	Clinical Criteria (Initial Approval)
Temozolomide (TEMODAR)	<p>Temozolomide may be covered when all the following criteria are met:</p> <ol style="list-style-type: none"> Patient has a diagnosis and staging of a cancer that: <ol style="list-style-type: none"> the requested medication is indicated for and is supported in one of the following: <ol style="list-style-type: none"> listed in the approved drug labeling (prescribing information); OR listed as a medically-accepted indication in compendia recognized by Medicaid; AND if the requested medication is to be used in combination with other chemotherapeutic, radiotherapeutic, or adjuvant therapies, then documentation of the entire regimen is required; AND

	<ul style="list-style-type: none"> c. if the requested medication is not indicated as a first line agent, then documentation of all previous therapies tried and failed, the duration, and reasons for stopping the therapy are required; <ul style="list-style-type: none"> i. if the agent was stopped for lack of benefit, documentation of what measures were used to define positive clinical response and what was the change at end of therapy from baseline; <ol style="list-style-type: none"> 2. Patient has received tests that confirm the diagnosis and staging including but not limited to: <ul style="list-style-type: none"> a. if an FDA-approved companion diagnostic test exists for the requested agent, then documentation that the test(s) were performed to confirm the diagnosis is required b. if a medically necessary test with adequate ability to confirm a gene-mutation exists, then documentation that the test(s) were performed to confirm the mutation as part of the diagnosis is required c. if any other companion tests have been used for concurrent or previous treatments, the documentation that the test(s) were performed is required; AND 3. The requested medication is prescribed by, or in consultation with, a specialist in oncology or neurology; AND 4. The patient does not have any contraindications to the requested medication or any other medications as part of the regimen; AND 5. The prescribed quantity and dosing regimen for the patient's age and other factors is within the manufacturer's published dosing guidelines or compendia recognized by Medicaid; AND 6. Documentation from the provider on how they will monitor and measure the patient and their condition to determine tolerability and patient-specific positive clinical response <p>If ALL criteria are met, the request will be approved for 6 months.</p> <p>If all criteria are not met, but there are documented medically necessary or situational circumstances, based on the professional judgement of the clinical reviewer, requests may be approved on a case-by-case basis up to the initial authorization duration.</p> <p>Criteria (Reauthorization)</p> <p>Temozolomide may be reauthorized when all the following criteria are met:</p> <ol style="list-style-type: none"> 1. Documentation of the change from baseline of the measures used to determine tolerability and patient specific positive clinical response; AND
--	--

	<p>2. If the requested medication is to be used in combination with other chemotherapeutic, radiotherapeutic, or adjuvant agents according to the approved drug labeling or medically-accepted indication, then documentation of all other appropriate chemotherapy agents, including those concurrently requested, for this regimen is required</p> <p>If ALL criteria are met, the request will be approved for 6 months.</p> <p>If all criteria are not met, but there are documented medically necessary or situational circumstances, based on the professional judgement of the clinical reviewer, requests may be approved on a case-by-case basis up to the reauthorization duration.</p>
--	--

Dosage and quantity limits:

Drug Name	Dose and Quantity Limits
Temozolomide (TEMODAR)	<p>Astrocytoma – Initial: 150mg/m² per day for 5 days of a 28 day cycle Astrocytoma – Maintenance: Up to 200mg/m² for 5 days of a 28 day cycle</p> <p>Glioblastoma – Initial: 75mg/m² per day up to 49 days Glioblastoma – Maintenance, cycle 1: 150mg/m² for 5 days of a 28 day cycle Glioblastoma – Maintenance, cycles 2 to 6: Up to 200mg/m² per day for 5 days of a 28 day cycle</p>

Coding:

HCPCS Code	Description
J8700	Temozolomide, oral, 5 mg
J9328	Temozolomide, injection, 1 mg

References

1. Temodar [package insert]. Whitehouse Station, NJ; Merck; November 2017.

History:

Date	Action and Summary of Changes
05.10.2021	Updating criteria to include radiotherapeutic per DUR board feedback
04.21.2021	Approved by DUR board
01.20.2021	Updating policy
07.25.2019	Formatting change
07.01.2019	New Policy